AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Lausanne, Switzerland, May 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended March 31, 2024, and…
Fri, 11 Oct 2024 03:42:00 GMT Here’s What Harris Must Do to Seal the Deal,” by Jonathan Martin: “This is an extraordinarily close race and [KAMALA] HARRIS must do more to signal that she’ll govern from the political center.” TRUMP ...
Wed, 09 Oct 2024 22:20:00 GMT CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF ...
Mon, 07 Oct 2024 17:00:00 GMT The fireside chat will take p AC Immune Reports Third Quarter 2023 Financial ... 2023 at 10:00am ET / 4 PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha ...
Mon, 07 Oct 2024 13:06:00 GMT Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off competition, a federal appeals court ruled on Monday.
Tue, 01 Oct 2024 15:00:00 GMT Before we begin, let me remind you that participants on this call will make forward-looking statements based on current expectations, and those statements are subject to certain risks and ...
